Arkansas one of several states weighing fluoride ban
Arkansas state Sen. Bryan King, a cattle and poultry farmer in Fayetteville, told CBS News he has "concerns" about adding fluoride to water.
Since 2011, when the state mandated most public drinking water to include fluoride, King has thrown his anti-fluoride voice behind a handful of bills seeking to repeal that mandate.
Fluoride is a natural mineral. It strengthens teeth and fights dental decay. It's been added to the U.S.'s public drinking supply since the 1940s.
The U.S. Centers for Disease Control and Prevention rated fluoride as one of the top ten public health achievements of the 20th century.
And according to the American Dental Association, "70 years of research, thousands of studies and the experience of more than 210 million Americans tell us that water fluoridation is effective in preventing cavities and is safe for children and adults."
"If that's the case, they need to individually go out to each water district and sell it to the people there, and let them make their own water decisions," King said.
At least 19 states have considered legislation to remove, ban or make fluoride optional in public drinking water this year. One of fluoride's most prominent critics is Health and Human Services Secretary Robert F. Kennedy Jr.
In the latest skirmish over science, fluoride opponents argue that at high levels, it can lead to kidney and liver damage and lower IQs in children.
The National Institutes of Health's toxicology program in 2024 determined "with moderate confidence" that there is a link between high levels of fluoride exposure and lower IQs in children. That conclusion was based on studies involving fluoride levels of about twice the recommended limit for drinking water.
The American Academy of Pediatrics has questioned the validity of the NIH's report, noting it had "important limitations," including the high fluoride levels, and that other reviews have come to different conclusions about fluoride's risks and benefits.
The EPA in 2011 lowered the recommended limit for fluoride in water to cut down on fluorosis — when spots appear on kids' teeth — and in the wake of a 2006 report from the National Academy of Sciences that found a lifetime of overconsumption of fluoride can lead to weakened, brittle bones and teeth.
At Arkansas' Fort Smith water system, Lance McAvoy, who oversees the system, told CBS News it's monitored 24/7.
"We actually take samples every 15 minutes to verify the online equipment," McAvoy said, adding there had never been an instance of significantly higher fluoride levels to date.
Dentists such as Kenton Ross, who also serves as president of Arkansas' dental association, say the science supporting fluoride is indisputable.
"You're gonna see a 25% reduction in tooth decay," Ross said of adding fluoride to drinking water. "We have over 75 years of research over community fluoridation."
For dentists, losing fluoride could mean losing the battle against tooth decay.
"It's gonna affect the children the worst because if they don't get it, we can't put it in later in life," Ross said.Alexander Tin and
Sara Moniuszko
contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Organ Preservation Market worth $0.3 billion by 2030 with 6.8% CAGR
DELRAY BEACH, Fla., July 21, 2025 /PRNewswire/ --The global Organ Preservation Market, valued at US$0.1 billion in 2024 stood at US$0.2 billion in 2025 and is projected to advance at a resilient CAGR of 6.8% from 2025 to 2030, culminating in a forecasted valuation of US$0.3 billion by the end of the period. The organ preservation market is experiencing robust growth fueled by rising incidence of chronic diseases, organ failure, and advancements in transplantation procedures. Increasing rates of end-stage organ conditions—such as kidney, liver, and heart failure—combined with a growing global demand for transplant procedures are key factors accelerating market expansion. The aging population, more susceptible to organ dysfunction, further highlights the increasing need for effective preservation methods to maintain organ viability pre-transplantation. Technological progress in preservation techniques, including hypothermic and normothermic perfusion, is transforming the standard of care by enhancing organ function and extending preservation times. In parallel, developing innovative preservation solutions such as the University of Wisconsin (UW) solution and Custodiol HTK significantly improves transplantation outcomes. Rising awareness among healthcare providers and the public about timely organ donation and preservation is increasing product adoption. Expanding hospital transplant programs, supportive government initiatives, and improved healthcare infrastructure in emerging markets also drive market momentum. Download PDF Brochure: Browse in-depth TOC on "Organ Preservation Market" 300 - Tables 100 - Figures 400 - Pages By solution, the organ preservation market, by solution, is categorized into UW Solution, Custodial HTK, Perfadex, and other solutions (including EuroCollins and Celsior). The UW (University of Wisconsin) solution accounted for the largest market share in 2024. This solution is widely used for preserving and flushing organs such as the liver, kidneys, and pancreas. As the first intracellular solution introduced for this purpose, it has become the benchmark in organ preservation. The dominance of the UW solution can be credited to its high efficacy in improving transplant outcomes. This is primarily due to the inclusion of metabolically inactive compounds like lactobionate and raffinose, which help reduce tissue damage, maintain cellular integrity, and enhance the physiological viability of organs during storage. These advantages have made the UW solution preferred over alternative preservation media. By technique, the static cold storage segment is expected to dominate the market due to its simplicity, cost-effectiveness, and widespread use in preserving kidneys, liver, and pancreas. While newer technologies such as hypothermic machines and normothermic perfusion are gaining traction, especially for heart and lung preservation, static cold storage remains the gold standard in many transplant centers worldwide. In addition, ongoing advancements in perfusion technologies and a growing focus on organ quality optimization before transplantation are expanding the market. The increasing initiatives by governments and non-profits to promote organ donation, along with improvements in preservation solutions and transportation logistics, are further contributing to market growth. As the demand for transplantable organs continues to outpace supply, efficient and advanced preservation methods become more crucial in ensuring transplant success. By organ type, Organ preservation, categorized by organ type, includes kidneys, liver, lungs, heart, and pancreas. In 2024, the kidney segment emerged as the leading contributor to the market. This prominence is primarily due to the rising prevalence of end-stage renal disease (ESRD), for which kidney transplantation remains the most effective treatment option. As kidney failure cases continue to grow, so does the number of transplant procedures, necessitating efficient preservation of donor kidneys before implantation in recipients. By end user, the organ preservation market is divided into transplant centers, hospitals, and specialty clinics. In 2024, the organ transplant centers segment accounted for the largest share of the market. The large share of this segment can be attributed to the extensive establishment of healthcare facilities that operate dedicated transplant programs. These centers are central to organ retrieval, preservation, and transplantation, making them critical consumers of preservation products and technologies. By geography, The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific region is attributed to supportive government policies, rising public awareness regarding organ donation, and a surge in organ donation activities. Countries like China and Japan have implemented standardized national guidelines for organ donation and transplantation, which are playing a key role in advancing the market. Additionally, improvements in healthcare infrastructure, the increasing burden of chronic illnesses, and the rise of medical tourism across several countries in the region are expected to fuel the market growth during the forecast period. Request Sample Pages : The prominent players in the global organ preservation market are Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions, Inc. (US), and TX Innovations (Netherlands). Paragonix (US): Paragonix is the leading market player in organ preservation. It operates mainly in the US and Europe. The company has been focused on developments such as new product launches, partnerships, agreements, and approvals since 2016. The company has developed devices for all thoracic & abdominal organ preservation. Paragonix also focuses on software services and tools for real-time organ tracking. Paragonix partnered with the Lung Transplant Foundation (US) to develop various technologies to improve donor lung preservation. In January 2021, the company partnered with Southwest Transplant Alliance (STA) to provide advanced organ preservation technologies. Such a development proves the company's strong market prevalence. XVIVO Perfusion AB (Sweden) XVIVO Perfusion AB is a prominent market and public domain company. It is headquartered in Sweden and operates in Europe, Asia, the Middle East, and North & South America. It spends nearly 31% of its revenue on R&D, which is why the company is involved in developing improved products for organ perfusion. XVIVO's lung perfusion solution is used mainly in Lung Preservation, making the solution a gold standard. In September 2020, XVIVO Perfusion entered an acquisition agreement with Organ Assist. This agreement further strengthened the company's product range and expanded its addressable market. Dr. Franz Kohler Chemie GmbH (Germany) Dr. Franz Kohler Chemie GmbH is a leading market player in organ preservation solutions since 1959. It involves developing electrolyte solutions, organ-protective solutions, therapeutics, antidotes, X-ray contrast agents, and medical devices. It has captured the market for Custodial, an organ preservation solution. Custodial holds advantages over other solutions, like reduced viscosity and an improved graft survival rate, and is widely used to preserve all organs, unlike other solutions. These advantages of a Custodial solution for organ preservation prove that Dr. Franz Kohler Chemie GMBH holds a substantial market prevalence. For more information, Inquire Now! Related Reports: Biopreservation Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Electrophysiology Market Human Organoids Market Transplant Diagnostics Market Get access to the latest updates on Organ Preservation Companies and Organ Preservation Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Forbes
an hour ago
- Forbes
Why Leaders Should View Transportation As A Healthcare Strategy
Miguel McInnis, President/CEO of Coordinated Transportation Solutions (CTS), a non-profit Non-Emergency Medical Transportation provider. From a public health perspective, transportation isn't top of mind when discussing care strategies for good health outcomes—but it should be. When patients miss regular doctor appointments, it can lead to worse health outcomes and higher healthcare costs—particularly for those who depend on Medicare or Medicaid to cover their healthcare expenses. Whether you're a health plan executive, benefits administrator or transportation provider, rethinking transportation can go a long way toward strategically improving compliance, return on investment and, most importantly, the overall public health of a community. The Access Imperative: The Long-Term Cost Of Missed Appointments When patients miss their appointments because they have no way of getting to them, this can have devastating effects on their health over time. Let's imagine a scenario with a patient we'll call Mrs. Jones. If Mrs. Jones isn't getting to her regular appointments to check her HbA1C levels, the consequences could be an exacerbation of her diabetes that will necessitate more serious care. This means Mrs. Jones will be more likely to utilize the emergency room. While Mrs. Jones will get the care she needs at that moment, it will likely be exponentially more (e.g., a co-pay of $1,000 compared to, say, a $30 primary care appointment). Plus, her situation could lead to repeated readmissions. How Leaders Can Help Improve Access Many people are unaware of what the appropriate use of the emergency room (ER) is—and that's understandable. Consumers aren't being told when going to the emergency room is actually inappropriate, so they may think that something like a bad cough warrants a visit to the ER. To help tackle this challenge, there needs to be a concerted effort to educate people on emergency room utilization. Businesses can help. Companies can create employee education to help workers learn how to use their benefits effectively. Likewise, health plans can incorporate a telehealth component into their coverage so when patients can't make it to an appointment in person, they can still get help from their doctor. Also, healthcare professionals can actively dissuade the use of the emergency room as a form of primary care. Together, employers, insurers and physicians can invest in solutions that encourage routine care and decrease no-shows, which can, in turn, reduce the need for high-cost interventions while supporting value-based care. Non-emergency medical transportation (NEMT) is a service provided to Medicaid beneficiaries, and this can help ensure that patients are getting the care they need. Unfortunately, this area of compliance can be a minefield. Transportation can, sadly, be rife with fraud, waste and abuse. One option to mitigate this is to use third-party brokers to handle the management of transportation logistics, scheduling and compliance reporting. These are not necessarily health plan providers' area of expertise, so having support available can help them meet regulatory requirements while lifting administrative burden, along with the risk of fraud, from their business operations. To ensure that the patients who need care most are able to access it, health plans can also partner with NEMT organizations to address the transportation-related social determinants of health with those transportation providers that specialize in underserved communities. Finally, supporting philanthropic organizations dedicated to reducing inequity and improving community metrics can help reduce missed appointments, boost disease control and lead to measurable population health benefits by funding project initiatives that incorporate transportation as part of an access to care solution. Why Leaders Should Act Now Reductions in public funding for healthcare could put already marginalized patients at risk of getting even less access to care than they currently have. However, this provides an opportunity for private businesses to lead in building access-driven care models. Filling this gap can lead to reduced emergency room visits and inpatient costs, new value-based care incentives, improved member satisfaction and plan retention and increased employee wellness and productivity. Transportation should not be treated as an afterthought. I believe businesses that make a strategic investment in this area will be ahead of the curve in terms of managing costs, making customers satisfied, increasing the wellness of their workforce and contributing to health equity. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Forbes
3 hours ago
- Forbes
A Data-Driven Fix For Orthopedic Practices Losing To Claim Denials
Sally Ragab, Founder & CEO @ Neunetix. Ask any orthopedic group what keeps their CFO up at night, and one answer dominates: denied claims. National surveys show that orthopedics now sees 9% to 11% of all claims rejected. In dollar terms, a 12-surgeon group billing $85 million a year could watch $8 to $10 million slip away before a single appeal is filed. In a recent article, I explored why the problem is worsening across healthcare. Building on this, a multisite analysis conducted by my company suggests that most leakage is preventable—and faster to plug than many administrators think. What We Studied Between April 2024 and March 2025, my company partnered with 12 independent orthopedic practices (across California, Texas, Florida and New York), which collectively submitted 1.26 million claims. We captured every rejection code, payer response time and downstream appeal outcome. Three findings stood out: 1. The overall claim denial rate dropped from 10.4% in the 12 months before the intervention to 6.7% during the six-month intervention period. 2. Preventable denials—such as those caused by missing claim modifiers or lapses in prior authorizations—fell from 64% to 28%. 3. Additionally, the average number of days that claims remained unpaid in accounts receivable decreased from 46 days to 38 days. To achieve this, all practices followed the same three-step process, which I will outline below. There was no need to hire additional full-time staff or change their electronic health record systems. Why Orthopedics Gets Hit Harder 1. High-Ticket Procedures: Hip- and knee-replacement bundles average between $30,000 and $32,000. One denial can wipe out the revenue from hundreds of physical therapy sessions—more than a year of visits for the average patient. 2. Modifier Complexity: Orthopedic procedures often involve complex coding and modifier usage, and many of the most frequently flagged CPT codes for CO-4 and PR-22 edits stem from this specialty—especially when modifiers are missing or missequenced. 3. Authorization Churn: Payers continue to ratchet up pre‑service checks. CMS now requires prior authorization for all hospital outpatient cervical spinal‑fusion procedures with disc removal, and insurance policies, like UnitedHealthcare's 2024 commercial policy, list every major arthroscopy CPT code as "prior authorization required." As a result, authorization‑related denials for outpatient claims jumped 16% in the past three years (registration required). The Three-Step Denial-Prevention Playbook Run a scrape and review electronic claims and payment files (known as ANSI 835/837 files) to identify which billing modifiers are most commonly linked to denials. In our cohort, simple left/right side coding errors (using -RT for right or -LT for left) accounted for 21% of preventable rejections. A one-hour meeting with the coding team to flag and prevent these errors led to a 2.3% point drop in the denial rate within just one month. Add a simple yes/no binary check to the scheduling system so that surgeries can't be booked unless a valid prior authorization ID is included. Clinics that enforced this safeguard reduced their authorization-related denials from 3.7% to 0.9% in just 90 days. A simple predictive model, trained on about 150,000 past claims, was used to flag new claims that were at high risk of denial. Only claims with a risk score of 0.70 or higher were sent to coders for review—everything else moved through automatically. This reduced the average coder workload by 41%, allowing staff to focus more on higher-value appeals. Financial Impact Across the 12 practices, net collections rose $6.4 million in the first six months—roughly $0.75 million per practice—while denial-related write-offs fell 52%. The average site reached cash-flow breakeven on the project in 51 days. Those numbers align with industry surveys, indicating that 65% of orthopedic denials are preventable and that 30% are never reworked at all. Quick Wins Orthopedic Leaders Can Implement Today As a summary, a focused audit of common billing modifier errors—followed by a short retraining session for coding staff—can lead to a 1.5 to 3 percentage-point drop in overall denials. This typically requires no more than two weeks. Next, adding a mandatory prior authorization field to the surgical scheduling system ensures that procedures can't be booked without a valid authorization ID. Clinics that adopted this safeguard saw authorization-related denials fall by 1 to 2.5 percentage points, with rollout taking about 30 days, including staff training. Finally, integrating a simple AI-based risk scoring tool into the claims submission process can further reduce denials by 2 to 4 percentage points. The tool should flag only the highest-risk claims for manual review, cutting coder workload by about 40% and letting teams focus on appeals and other high-value tasks. In my experience, most practices can launch this model within 60 days. Collectively, these steps can push denial rates below the 7.66% improper payment benchmark CMS reports for 2024. Why Act Now • Payer scrutiny is rising. The "State of Claims 2024" report notes a steady climb in authorization-related denials across all specialties, with orthopedics singled out for high-cost implant cases. • Providers feel the pinch. In Experian's 2024 survey, 73% said denials are rising and 67% said payments are taking longer to arrive. • CMS audits are looming. Improper payment probes increasingly target spinal and total-joint bundles; denial records factor into audit risk scores. The Bottom Line Denied claims shouldn't simply be a cost of doing business—they're a solvable data problem. Our field data proves that taking steps like a disciplined five-day audit, a hard scheduling gate and a modest machine-learning layer can slash orthopedic denial rates by one-third and return millions to the bottom line within a quarter. Your implants are cutting-edge—your denial-defense strategy should be too. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
